FY2027 Earnings Estimate for SLN Issued By William Blair

Silence Therapeutics plc (NASDAQ:SLN) – Analysts at William Blair raised their FY2027 earnings per share estimates for Silence Therapeutics in a report released on Thursday, May 8th. William Blair analyst M. Minter now expects that the company will post earnings per share of $13.66 for the year, up from their previous estimate of $13.57. The consensus estimate for Silence Therapeutics’ current full-year earnings is ($1.77) per share. William Blair also issued estimates for Silence Therapeutics’ FY2028 earnings at $24.35 EPS.

Silence Therapeutics (NASDAQ:SLN) last posted its quarterly earnings data on Thursday, May 15th. The company reported ($0.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.42). Silence Therapeutics had a negative net margin of 342.00% and a negative return on equity of 62.81%. The company had revenue of $0.14 million for the quarter, compared to analysts’ expectations of $3.58 million.

Other research analysts have also recently issued reports about the company. HC Wainwright reaffirmed a “buy” rating and set a $75.00 price objective on shares of Silence Therapeutics in a research report on Friday, March 7th. BMO Capital Markets lowered their price objective on Silence Therapeutics from $67.00 to $25.00 and set an “outperform” rating on the stock in a research report on Tuesday, March 4th. Chardan Capital lowered their price objective on Silence Therapeutics from $55.00 to $35.00 and set a “buy” rating on the stock in a research report on Friday. The Goldman Sachs Group lowered their price objective on Silence Therapeutics from $4.00 to $3.00 and set a “sell” rating on the stock in a research report on Friday. Finally, Morgan Stanley lowered their price target on Silence Therapeutics from $45.00 to $25.00 and set an “overweight” rating on the stock in a report on Friday. One analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Silence Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $33.83.

Silence Therapeutics Stock Up 3.9%

SLN stock opened at $3.70 on Monday. Silence Therapeutics has a twelve month low of $1.97 and a twelve month high of $24.38. The stock has a market cap of $110.74 million, a P/E ratio of -2.36 and a beta of 1.20. The business’s 50-day moving average price is $3.39 and its 200-day moving average price is $6.41.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in SLN. Barclays PLC raised its holdings in shares of Silence Therapeutics by 83.8% during the 4th quarter. Barclays PLC now owns 6,126 shares of the company’s stock worth $42,000 after acquiring an additional 2,793 shares in the last quarter. JPMorgan Chase & Co. purchased a new stake in shares of Silence Therapeutics during the 4th quarter worth approximately $26,000. GAMMA Investing LLC raised its holdings in shares of Silence Therapeutics by 609.2% during the 4th quarter. GAMMA Investing LLC now owns 6,092 shares of the company’s stock worth $42,000 after acquiring an additional 5,233 shares in the last quarter. Virtus ETF Advisers LLC raised its holdings in shares of Silence Therapeutics by 130.5% during the 4th quarter. Virtus ETF Advisers LLC now owns 10,772 shares of the company’s stock worth $74,000 after acquiring an additional 6,098 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. purchased a new stake in shares of Silence Therapeutics during the 4th quarter worth approximately $69,000. 98.73% of the stock is owned by hedge funds and other institutional investors.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.